LGALS3 and coronary artery disorder: Ana Lorenzo-Almorós et al. found that Galectin-3 is associated with an increased risk of cardiovascular events in diabetic patients with stable CAD; galectin-3 may work as a diagnostic and prognostic biomarker (Lorenzo-Almoros et al., 2020).